ASH 2021 | MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the trial design of the open-label, randomized Phase III MAJIC trial (NCT05057494), which will investigate acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, with venetoclax versus obinutuzumab with venetoclax in patients with relapsed/refactory chronic lymphocytic leukemia (CLL). Therapy duration in both arms will be based on minimal residual disease (MRD) status, where patients will either receive 12 or 24 months of venetoclax. This trial will aim to assess whether BTK inhibitors or antibodies are the best approach for CLL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Matthew Davids, MD, has received consultancy fees from AbbVie, BeiGene, Adaptive Biotechnologies, Janssen, Takeda, Merck, Eli Lilly and Company, and Celgene; consultancy fees and research funding from Pharmacyclics, Astra-Zeneca, BMS, TG Therapeutics, Genentech, MEI Pharma, Novartis, Verastem, Ascentage Pharma, and Surface Oncology.
